Ontology highlight
ABSTRACT:
SUBMITTER: Wang JH
PROVIDER: S-EPMC8774110 | biostudies-literature | 2022 Jan
REPOSITORIES: biostudies-literature
Wang Jing-Houng JH Chen Yen-Yang YY Kee Kwong-Ming KM Wang Chih-Chi CC Tsai Ming-Chao MC Kuo Yuan-Hung YH Hung Chao-Hung CH Li Wei-Feng WF Lai Hsiang-Lan HL Chen Yen-Hao YH
Cancers 20220111 2
Atezolizumab plus bevacizumab has been approved as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma (uHCC). This study was designed to assess the clinical impact of atezolizumab plus bevacizumab in uHCC patients. A total of 48 uHCC patients receiving atezolizumab plus bevacizumab were identified, including first-line, second-line, third-line, and later-line settings. In these patients, the median progression-free survival (PFS) was 5.0 months, including 5 ...[more]